IGF::OT::IGF OMICS-CHIPS FOR CTC ISOLATION AND MOLECULAR ANALYSIS

单细胞基因组学已经成为一个新的前沿，代表着技术和生物的独特融合。在这个SBIR项目中，Neomeics公司提议为循环肿瘤细胞(CTCs)的单细胞蛋白质组学和代谢组学开发一个新的平台。我们将开发一种突破性的全集成OMICS芯片来分离CTCs，并对分离的单个CTCs进行高灵敏度和高通量的质谱学分析。在第一阶段，我们建议开发一种多层、多模块的CTC芯片，用于从人血中分离(浓缩、分选和选择)单个CTCs。我们将使用添加CTC的血液样本开发和测试CTC芯片，并使用转移性癌症患者的临床样本验证其性能。如果我们的第一阶段项目成功，在未来的第二阶段，我们将通过将CTC芯片与我们突破性的多喷口发射器阵列(MEA)芯片集成在一起来开发Omics芯片。我们的Omics芯片将作为一个通用平台，使包括CTCs在内的稀有和异种细胞的单细胞组学成为可能。从单细胞水平对CTCs进行OMICS分析所获得的生物学/临床经验将有助于阐明肿瘤转移的起始、发展和预后，从而为个体化治疗和规避耐药性提供新的策略。

Single Cell Omics has become a new frontier and represents the unique convergence of technology and biology. In this SBIR project, Newomics Inc. proposes to develop a new platform for single cell proteomics and metabolomics of circulating tumor cells (CTCs). We will develop a groundbreaking and fully-integrated Omics-chip to isolate CTCs and perform high-sensitivity and high-throughput mass spectrometry-based analysis of isolated single CTCs. In the Phase I, we propose to develop a multi-layer and multi-module CTCchip for isolation (enrichment, sorting, and selection) of single CTCs from human blood. We will develop and test the CTC-chips using CTC-spiked blood samples, and validate their performance using clinical samples from metastatic cancer patients. If our Phase I project is successful, in the future Phase II stage, we will develop Omics-chips by integrating CTC-chips with our breakthrough multinozzle emitter array (MEA) chips. Our Omics-chip will serve as a universal platform to enable single cell omics of rare and heterogeneous cells including CTCs. The biological/clinical lessons learned from Omics analysis of CTCs at the single cell level will help elucidate the metastatic initiation, development, and prognosis, thereby providing new strategies for personalized therapies and for circumventing drug resistance.